Abstract

The rising global prevalence of obesity has motivated the search for new, effective, and sustainable treatment techniques beyond traditional dietary and pharmaceutical approaches. Emerging data underscores the crucial role of the gut bacteria in energy control, metabolic function, and systemic inflammation. Disruptions in microbial composition termed dysbiosis have been substantially correlated with obesity and related metabolic diseases. While probiotics offer a potential route for restoring microbial balance, their therapeutic efficacy is generally hindered by poor gastrointestinal survival and non-specific dispersion. This work proposes a unique intervention technique that combines probiotics with nanoparticle-based delivery systems. These designed nanocarriers boost probiotic viability, allow targeted distribution to intestinal areas, and regulate gut microbiota with precision. By boosting beneficial bacteria taxa, lowering lipogenic activity, and regulating metabolic hormones, nanoparticle-mediated probiotic therapy indicates significant promise for non-invasive, individualized obesity management. The research further explores molecular insights, preclinical discoveries, and translational approaches toward clinical use, presenting this strategy as a frontier in microbiome-based medicines.